A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth

Trial Profile

A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2016

At a glance

  • Drugs Hydroxyprogesterone (Primary)
  • Indications Preterm birth
  • Focus Adverse reactions
  • Sponsors AMAG Pharmaceuticals; Hologic; Lumara Health
  • Most Recent Events

    • 10 Dec 2015 Planned End Date changed from 1 Dec 2016 to 1 Oct 2020 as reported by Clinicaltrials.gov.
    • 10 Dec 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Aug 2020 as reported by ClinicalTrials.gov.
    • 21 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top